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Abstract
Background: Infants born at extreme prematurity (below 28 weeks' gestation) are at high risk of
developmental disability. A major risk factor for disability is having a low level of thyroid hormone
which is recognised to be a frequent phenomenon in these infants. At present it is unclear whether
low levels of thyroid hormone are a cause of disability, or a consequence of concurrent adversity.
Methods: We propose an explanatory multi-centre double blind randomised controlled trial of
thyroid hormone supplementation in babies born below 28 weeks' gestation. All infants will receive
either levothyroxine or placebo until 32 weeks' corrected gestational age. The primary outcome
will be brain growth. This will be assessed by the width of the sub-arachnoid space measured using
cranial ultrasound and head circumference at 36 weeks' corrected gestational. The secondary
outcomes will be (a) thyroid hormone concentrations measured at increasing postnatal age, (b)
status of the hypothalamic pituitary axis, (c) auxological data between birth and 36 weeks'
corrected gestational age, (d) thyroid gland volume, (e) volumes of brain structures (measured by
magnetic resonance imaging), (f) determination of the extent of myelination and white matter
integrity (measured by diffusion weighted MRI) and brain vessel morphology (measured by
magnetic resonance angiography) at expected date of delivery and (g) markers of morbidity
including duration of mechanical ventilation and chronic lung disease.
We will also examine how activity of the hypothalamic-pituitary-adrenal axis modulates the effects
of thyroid supplementation. This will contribute to decisions about which confounding variables to
assess in large-scale studies.
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Background
In the immediate postnatal period of babies born at term,
hypothyroidism causes neurodevelopmental disabil-
ity[1,2]. This disability can be prevented by giving supple-
mentary thyroid hormone[3,4]. Infants born at extreme
prematurity (i.e. before 28 weeks' gestation) are at high
risk of neurodevelopmental disability, particularly if they
are hypothyroid [4-6]. Some, but not all, forms of thyroid
supplementation appear to reduce the incidence of poor
neurodevelopmental outcome in infants born at extreme
prematurity [7-9].
Hypothyroidism in early infancy causes 
neurodevelopmental disability which can be prevented by 
giving supplementary thyroid hormone
In congenital hypothyroidism (CH) early treatment with
thyroid replacement reduces severe developmental defi-
cits[1]. Even mild thyroid hormone insufficiency can pro-
duce measurable, but preventable, deficits in
neuropsychological functions[3,4]. Magnetic resonance
imaging (MRI) and spectroscopy (MRS) have docu-
mented brain metabolic changes in untreated CH. The
reversal of these abnormalities following replacement
therapy is thought to be due to improved myelina-
tion[10]. This suggests an important role for thyroid hor-
mone in the developing brain in the early postnatal
period.
Infants born before 28 weeks of gestation are at high risk 
of disability
Advances in neonatal medicine have resulted in an
increase in survival of preterm infants below 28 weeks'
gestation. Infants born extremely prematurely at this low
gestation are at particular risk of neurological abnormali-
ties [11-13]. The normal development of the brains of
these infants is at high risk of disruption with consequent
acquired damage especially to the white matter because of
multiple factors[14]. These are thought to include hypoxic
ischaemia, free radical injury because of low concentra-
tions of antioxidants, undernutrition and sepsis[15]. This
period in brain development is important because neuro-
nal migration has only just finished (at about 20 weeks)
and synaptogenesis is occurring and therefore the cellular
milieu is critical[16].
Brain MRI studies of survivors of low birth weight, who
have subtle cognitive abnormalities have been shown to
have diminished volumes of the caudate nucleus and hip-
pocampus and these findings have been correlated with
lower IQ, learning disorder and attention deficit[17,18].
Recent brain MRI studies of preterm infants also show
that quantitative cerebral structural abnormalities are
related to the degree of immaturity at birth and are fol-
lowed by abnormal neurodevelopmental out-
come[14,19]. Preterm infants assessed at term show
reduced myelination when compared to infants born at
term[14].
Evidence of hypothyroidism is common among infants 
born before 28 weeks of gestation and is associated with 
an increased risk of disability
Transient hypothyroxinaemia of prematurity as character-
ised by low blood thyroxine (T4) concentrations with nor-
mal or mildly elevated plasma thyroid stimulating
hormone (TSH) concentrations is common in infants
under 30 weeks' gestation at birth, occurring in up to
69%[9,20-23]. The proportion of preterm infants having
hypothyroxinaemia increases with decreasing gestational
age[22,24]. A recent large collaborative Scottish study has
shown that an extremely premature group of infants of
23–27 weeks' gestation appeared distinctive and were
hypothyroxinaemic relative to other groups[20]. The post-
natal surge of T4 concentrations described in the term
infants was less marked in infants of 31–34 weeks gesta-
tion, absent in infants of 28–30 weeks and reversed in
infants of 23–27 weeks who had low plasma T4 concen-
trations.
Low blood thyroid hormone concentrations in the first
few weeks of life in preterm infants have been linked with
poor neurodevelopment[5,6]. Reuss et al[25] (n = 463)
found a 4-fold increased risk of disabling cerebral palsy at
2 years of age associated with hypothyroxinaemia in
infants born below 33 weeks' gestation. Den Ouden et
al[26] (n = 563) found a higher incidence of neurologic
dysfunction at 5 and 9 years of age in association with
lower thyroxine concentrations even after adjustments for
other perinatal factors in preterm infants born below 32
weeks'. Paul et al[27] found increased mortality and
increased incidence of intraventricular haemorrhage in
preterm infants with abnormal thyroid function, whilst
Leviton et al[26] reported white matter changes predictive
of abnormal neurological outcome on cranial ultrasound
of neonates with low T4 blood concentrations. In addi-
tion, published data have documented a relationship
between maternal thyroid deficiency during pregnancy
and problems with neuropsychological development of
the offspring[28]. However, the questions of whether this
hypothyroidism reflects the adversity leading to brain
injury, or whether hypothyroidism is a preventable cause
of brain injury can only be answered by randomised con-
trolled clinical trials.
Thyroid supplementation to extreme preterm infants may 
reduce the risk of disability
A randomised controlled trial of T4 supplementation by
Van Wassanaer et al[8,21] showed an improved Bayley
Mental Development Index (MDI) and Psychomotor
Development Index (PDI) at 2 years among infants born
at extreme prematurity who had received T4 supplemen-Trials 2008, 9:17 http://www.trialsjournal.com/content/9/1/17
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tation. However, the babies who appeared to benefit were
not the primary target population in this study and the
positive result was only evident after subgroup analysis. In
the whole sample there was no benefit to long term out-
come. The reliability of that trial was limited by a small
sample size. In other studies, thyroid hormone replace-
ment has been given to preterm infants with either bene-
ficial effects or no apparent effects[7,9,21,29,30].
However, the studies which have been done are of small
sample size and have not shown rigorous proof of efficacy
of such a treatment.
Previous studies of thyroid replacement therapy in preterm 
infants
A Cochrane review of thyroid hormone supplementation
in premature infants found that none of the available tri-
als provide good evidence for the value of thyroid hor-
mone supplementation in preterm infants[31]. The
results of the meta-analysis found no significant differ-
ence in overall mortality. Meta-analysis of two stud-
ies[7,8] found no significant difference in Bayley MDI or
PDI performed at 7–12 months, death or IQ score at 5.7
years of age. All studies were of small size with the largest
by van Wassanaer[8], which enrolled 200 infants under
30 weeks' gestation. However, the sample size for this post
hoc subgroup analysis of infants with gestational age
below 27 weeks who benefited from the intervention was
small comprising just 46 infants (19 in the treatment arm
and 27 in the placebo arm). The review concluded that
future trials of sufficient size needed to be undertaken to
detect the clinically important differences in neurodevel-
opmental outcome, particularly enrolling the infants
most likely to benefit from thyroid hormone therapy such
as extremely preterm infants.
The conclusion from these results is that there is biologi-
cally plausible evidence that T4 supplementation for very
immature babies may improve their neurological out-
come, but that more mature babies are not likely to bene-
fit from this intervention. Studies of triiodothyronine (T3)
supplementation[22,30] have not provided evidence for
improved outcome. Animal studies have shown that the
postnatal development of brain structures in rats was
entirely dependent on local generation of T3 from T4 by
type 2 iodothyronine deiodinase[32,33]. This suggests
that normal neurodevelopment requires appropriate T4
supplementation and not T3 supplementation. T3 supple-
mentation appeared to raise plasma free T3 and total T3
concentrations but suppress T4 concentrations[34,35]. T4
supplementation has been shown to suppress T3 concen-
trations but raise total and free T4 concentrations
(FT4)[7,8]. Van Wassanaer et al examined different T4
dosage schemes and concluded that 8 mcg/kg birth-
weight/day increased T4 and FT4 concentrations most
appropriately and prevented transient hypothyroxinae-
mia during the 6 weeks' treatment[35]. Van Wassanaer
also showed that high longitudinal FT4 concentrations
were not associated with worse outcome, while low FT4
concentrations were associated with worse neurodevelop-
mental outcome at 2 and 5 years of age[35]. In the light of
these findings, a trial of T4 supplementation is a strong
candidate for intervention.
An important practical issue for intervention studies is the
need to classify the thyroid status of individual infants.
The blood concentrations used in this classification will
determine recruitment to the study and the response to
monitoring during the intervention. At present, it remains
unclear what cut-off point for T4 or FT4 concentrations
constitutes hyperthyroxinaemia or hypothyroxinaemia in
these preterm infants, particularly in the weeks just after
birth. Normative values for thyroid hormones in cord
blood for each gestational age have been pub-
lished[20,24]. It has been suggested that these values can
provide normative values in the postnatal period by relat-
ing concentrations at a particular corrected gestational age
to those of infants born at the same gestational age[20].
However, the implications of this strategy have not been
explored in treated infants. We will be able to model the
implications of this strategy using the results of this trial.
The associations of transient hypothyroidism have not 
been studied among infants born at extreme prematurity
Following birth, thyroid status changes and these changes
are influenced by gestational age at birth. The conse-
quences of these changes have not been reported. Longi-
tudinal measures of thyroid status and neonatal progress
will be made during this trial and will allow us to describe
how thyroid status in the weeks after birth at extreme pre-
maturity is related to neonatal course.
Thyroid status may affect other organ systems in ways that 
affect the design of future trials
Thyroid hormones alter metabolic rate[2,28]. Nutritional
and growth implications of hypothyroidism have not
been studied. Thyroid supplementation could increase
nutritional requirements and reduce extrauterine growth.
To date, there is little evidence of this occurring among
infants born at extreme prematurity. Given that neurode-
velopmental outcome may be confounded by the social
environment after discharge[13,36], it will be important
to include neuroradiological markers of brain develop-
ment as an intermediate outcome. However, although
thyroid hormones are involved in brain development,
particularly in myelination[10,37,38], there is a paucity of
published data concerning the relationship between thy-
roid hormone status and brain development in preterm
infants. The lack of information about how thyroid status
relates to brain size and body growth will hinder clinical
trials of thyroid supplementation.Trials 2008, 9:17 http://www.trialsjournal.com/content/9/1/17
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Other factors may be relevant to the effects of thyroid 
supplementation on outcome
Factors which may contribute to abnormal thyroid func-
tion in very preterm infants include: immaturity of the
thyroid gland, immaturity of the hypothalamic-pituitary-
thyroid axis, disruption of maternal transfer of T4 through
the placenta, relative immaturity of type 1 deiodothyro-
nine monodeiodinase enzyme systems and reduction in
thyroid binding globulin (TBG) due to hepatic immatu-
rity[2,23]. Iodine is required for renewal of intra-thyroidal
T4, but the concentrations of iodine in the thyroid gland
of preterm infants are low[39,40]. This appears to be
related to maternal iodine status and effect of inadequate
iodine supplementation in parenteral nutrition for pre-
term infants [39-41].
Abnormal thyroid size is often found in disease states, e.g.
goitre[2]. Thyroid size may therefore be a useful marker of
thyroid status. However, the only normative study of thy-
roid size in term infants was limited to 100 infants and
did not examine infants born at extreme prematurity[42].
Blood cortisol concentrations decrease as blood T4 con-
centrations increase with advancing gestational
age[34,43]. These observations suggest that there may be
an interaction between the cortisol and thyroid systems in
preterm infants. Since both hormones have been impli-
cated in early brain development[44,45], this interaction
could contribute to the poor neurological outcome of
infants born extremely premature. Activity of the hypoth-
alamic-pituitary-adrenal (HPA) axis is central to normal
fetal development and neonatal transition[46,47].
Extremely premature infants have low basal blood cortisol
concentrations and inadequate stimulated cortisol
responses to adrenocorticotrophic hormone in the early
neonatal period[44,47]. Cortisol is important for survival
during illness and cortisol concentrations are expected to
increase during significant stress. In ill adults with low
baseline and stimulated cortisol concentrations, mortality
is higher[44]. In the preterm infant population, the phys-
iological significance of lower blood cortisol values
remains unclear[46,47]. Most studies have not consist-
ently correlated blood cortisol concentrations to physio-
logical markers of cortisol effect and outcome in preterm
infants. In a recent study, the HPA axis was found to be
unresponsive to standard stimulation tests until 11 days
of age in preterm baboons indicating HPA axis immatu-
rity[48]. Activation of the HPA axis and increased blood
cortisol concentrations may be essential to respond to the
many stressors of extra-uterine existence in the extreme
preterm infants. This transient inability of the adrenals to
maintain cortisol homoeostasis in premature newborns
in the immediate postnatal period has been described as
transient adrenocortical insufficiency of prematurity[44].
Valerio et al[30] looked at the effect of thyroid hormone
supplementation on blood cortisol concentrations in
babies born below 28 weeks GA. The sample size was
small with only 31 patients. No significant difference was
noted in cortisol concentrations and mortality between
the groups. The results of the study suggest that hypothy-
roxinaemia was not involved in the development of
hypocortisolism in preterm infants. However, the
medium-term effects of the relationships between these
two endocrine systems have not been studied. Further
understanding of their roles in the outcome of preterm
infants is needed.
Possible negative effects of giving T4
Thyroxine is infrequently given to extremely premature
babies. The only adverse effect that might be predicted is
based on clinical experience of giving the drug to more
mature patients, namely a persistent tachycardia. The drug
may increase metabolic rate. In the critical paper by van
Wassanaer et al[8], there was no difference in neurodevel-
opmental outcome as a result of T4 supplementation.
However, a post hoc subgroup analysis showed that more
mature babies who were given T4 supplementation had a
worse neurodevelopmental outcome than those who
were unsupplemented. The mechanism for this possible
effect is not known.
Levothyroxine pharmacokinetics
There has been no previous work in this patient group on
the circulating blood concentrations of thyroid hormones
following the administration of levothyroxine. Establish-
ing whether each infant has similar circulating blood con-
centrations will be an important aspect of the explanatory
RCT. We will use population pharmacokinetic tech-
niques. These will allow us to derive information about
circulating thyroid hormone concentrations using meas-
urements done on blood samples taken during routine
clinical practice.
In summary, the literature indicates that several areas of
uncertainty will hamper randomised controlled studies of
interventions for hypothyroidism in extremely preterm
infants. These areas include: the optimal timing of moni-
toring, whether it is appropriate to use reference ranges
based on cord blood values, the effect of cortisol status on
thyroid function and the relationship between thyroid
status and HPA axis. None of these issues can be clarified
unless infants who receive thyroid supplementation are
prospectively compared to infants who do not receive thy-
roid supplementation.
In the light of the issues outlined above, an explana-
tory[49] randomised controlled trial of thyroid supple-
mentation is proposed in infants below 28 weeks'
gestation, with an assessment of its effect on short termTrials 2008, 9:17 http://www.trialsjournal.com/content/9/1/17
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explanatory outcomes. This study will markedly enhance
the design and interpretation of future large-scale studies
aimed at determining the effect of such supplementation
on long term neurodevelopmental outcome.
There is therefore an urgent need for a larger scale study to
discover whether thyroid supplementation benefits these
very premature babies. This proposed study will examine
the effects of one commonly used form of thyroid supple-
mentation on key intermediate outcomes in these infants.
We will also extend previous work in this area by explor-
ing perinatal factors which could modulate the effects of
thyroid supplementation
Aims of the study
To determine how treatment with levothyroxine (LT-4)
postnatally until 32 weeks corrected gestational age
(CGA) modulates brain size and development, the
hypothalamic-pituitary-adrenal axis (HPA) and somatic
growth in a randomised double blind placebo-controlled
trial.
Objectives
Primary Outcome
￿ Effect of levothyroxine therapy on brain size as assessed
by the width of the subarachnoid space [54] measured at
36 weeks CGA using cranial ultrasound and serial head
circumference as an index of brain weight[50,51].
Secondary Outcomes
(a) Serial head circumference as an index of brain weight
(b) Longitudinal thyroid hormone concentrations
between birth and expected date of delivery;
(c) Cortisol hormone status between birth and expected
date of delivery
(d) Auxological data at pre-randomisation, day 14, day
21, day 28 and at 36 weeks' CGA
(e) Thyroid gland size measured by ultrasound imaging
(f) Mortality
(g) The volumes of key brain structures, whole brain vol-
ume, extent of myelination of cerebral white matter and
white matter integrity and brain vessel morphology using
brain MRI examinations at term equivalent
(h) Duration of mechanical ventilation/oxygen require-
ment
(i) Chronic lung disease requiring home oxygen at dis-
charge
Methods
Trial Design
A multicentre double blind randomised placebo control-
led trial of levothyroxine given postnatally to infants born
under 28 weeks' gestation until 32 weeks' CGA. Parents,
care providers and outcome assessors will be blind to the
allocation of placebo and levothyroxine.
Inclusion Criteria
a) Infants with gestational age under 28 weeks at birth*
b) Recruitment within five days of birth
c) Single or multiple births
*The assessment of gestational age will be based on the
working estimate available in the obstetric notes at the
time of delivery (corrected gestational age).
Exclusion Criteria
a) Infants born to mother with known thyroid disease or
on antithyroid medications during pregnancy will be
excluded.
b) Infants born to mother who are on amiodarone during
pregnancy will be excluded.
c) Infants diagnosed with major congenital or chromo-
somal abnormalities known to affect thyroid function or
brain development will be excluded.
d) Maternal death during or within 5 days after childbirth.
Randomisation
Once all inclusion and exclusion criteria are met and
informed consent has been obtained, infants will be
included in the study and allocated a randomisation
number. The randomisation lists will be computer gener-
ated with random variable block lengths using the statis-
tical package STATA. The randomisation list will be
stratified by centre, and gestational age at birth (under 25
weeks' gestation, 25–26 weeks' gestation, 27–27+6 weeks'
gestation). Multiple births will follow the randomisation
process as per singleton births: each sibling in a multiple
birth will receive the same treatment allocation.
Concealment of allocation will be provided by pharmacy
departments of the respective hospitals. The randomisa-
tion list will be stored in a locked filing cabinet in the
pharmacy Departments of each hospital and access will be
limited to the pharmacist involved in the study.
Blinding and Unblinding
Parents, investigators, clinicians involved in patient care
and individuals assessing and analysing study end-pointsTrials 2008, 9:17 http://www.trialsjournal.com/content/9/1/17
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will all be blinded to the allocated study treatments. Lev-
othyroxine and its placebo will be presented identically
(see below). In the event that unblinding is necessary,
there will be 24 hour access for unblinding and an
Unblinding Case Report Form will be completed. In most
cases, stopping the 'treatment' should be sufficient with-
out the need for unblinding. Before unblinding is done,
the case will be discussed with the Chief Investigator or in
his absence a delegated member of the Trial Management
Group.
Treatment Regimen and Dosage
We will use two forms of the active medication: intrave-
nous levothyroxine (tradename: Levothyroid) and oral
levothyroxine solution (tradename: Evotrox) with corre-
sponding placebos during the study period.
In the initial phase, infants will receive either intravenous
Levothyroid or placebo (5% dextrose) within the first 5
days after birth. The treatment regimen will follow the
dosage guidelines determined by previous studies[8,52] at
8 mcg/kg birthweight/day single daily dose.
In the next phase, once enteral feeds are fully established,
oral solution Evotrox or placebo (carrier solution without
active drug) will be given at 8 mcg/kg birthweight/day sin-
gle daily dose until the baby reaches 32 weeks CGA.
Study Medication
The intravenous levothyroxine (Levothyroid) medication
is a powder and is dissolved in 5% dextrose and albumin
and aliquots are put into syringes aseptically by the Phar-
macy Department at the Royal Liverpool and Broadgreen
University Hospital. Albumin is added to the reconstitu-
tion based on previous similar work done by van Wassa-
naer et al[8]. The addition of a small amount of albumin
results in a more stable solution with no decomposition
products and little possibility of losses due to adsorbtion/
absorption of levothyroxine into the syringe. The addition
of albumin therefore allows for the availability of free thy-
roxine. Stability testing for the levothyroxine was per-
formed by Quality Control North West.
Levothyroid is manufactured in Spain by Aventis Pharma,
Marketing Authorisation 971622. It is imported by IDIS
Ltd and prepared under EU Good Manufacturing Practice
at Royal Liverpool University. Placebo will be an equal
volume of 5% dextrose presented in an identical manner
to the Levothyroid.
Evotrox is an oral solution and is manufactured in the
United Kingdom by Kappin Ltd, Marketing Authorisation
PL20249/0007. The placebo form is prepared by the Phar-
maceutical company under the terms of their Marketing
Authorisation as the identical carrier substance without
the active ingredient. Dispensing and blinding is by the
Pharmacy Departments at recruiting centres.
Blood and Saliva Sampling
Infants: All infants will undergo blood investigations.
Each sample will require approximately 0.5 ml of blood
and this is arranged to coincide with routine blood tests
obtained during the clinical care of the infant at the neo-
natal unit
TT4 (total thyroxine), FT4 (free T4), TT3 (total T3), FT3
(free T3), TSH (thyroid stimulating hormone) blood con-
centrations will be measured before treatment begins
(baseline) and on Day 14, Day 21, Day 28 and 36 weeks
(corrected age).
A subset population of infants may have more frequent
blood tests for thyroid function to test the bioavailability
and pharmacokinetics of the drug. The blood test will be
done at different times of the day on different babies and
this is arranged to coincide with routine blood tests
obtained during the clinical care of the infant at the neo-
natal unit. Consent will be obtained separately from the
parents of these infants. Since treatment allocation will be
concealed, some of these infants will be receiving placebo.
Comparison of drug concentrations between the two
treatment groups will allow us to take account of back-
ground variation in blood thyroid concentrations.
All infants will have saliva collected from the mouth (100
microlitres) at three separate times of the day before treat-
ment begins (baseline), on day 14, Day 28 and 36 weeks'
CGA.
Early morning cortisol and ACTH concentrations will be
obtained before treatment begins (baseline), on Day 14,
Day 28 and 36 weeks CGA.
Mother of infant(s) enrolled: 5 ml of blood for TT4, FT4,
TT3, FT3, TSH, thyroid peroxidase antibody (TPO), corti-
sol and thyrotropin receptor antibody (TRAB) will be
obtained as soon as possible from mothers of infants who
are enrolled to the study. These results will be reviewed by
the study team and abnormal results will be referred to a
Consultant Endocrinologist, who will liaise with the
mother's Obstetrician about any follow-up that is
required.
Growth and Auxology
All infants will be measured for weight, lower leg length
(using knemometry) and occipito-frontal circumference
before commencing treatment (baseline), day 14, day 21,
day 28 and at 36 weeks' CGA.Trials 2008, 9:17 http://www.trialsjournal.com/content/9/1/17
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Brain Imaging
Cranial ultrasounds will be performed according to the
Neonatal Unit's protocol. There will be study scans at 36
weeks' CGA and routine images will be supplemented by
measurements of width of the subarachnoid space.
MRI examination of the brain will be performed at term
equivalence in infants for whom separate informed paren-
tal consent will be obtained, at the MRI department of the
Royal Liverpool Children's Hospital, Liverpool or Well-
come Trust Clinical Research Facility, Manchester. Data
acquisition is not expected to exceed 40 minutes. No seda-
tion will be used, as infants will be imaged during natural
sleep after having been fed. Careful infant positioning by
the radiographer and temperature maintenance will
ensure their comfort while being scanned.
Thyroid Imaging
We will also measure thyroid gland size using ultrasound
at 36 weeks' CGA. These data will be compared to pub-
lished normative data for measurements of thyroid size in
utero and [53]in term infants[42]. In conjunction with
detailed characterisation of thyroid hormone status, this
will provide a novel insight into how prematurity affects
the thyroid axis.
Summary of Investigations and Procedures
Processing of Blood and Saliva Samples
All blood samples will be processed according to standard
practice and sent to the laboratories at the Royal Liverpool
Children's Hospital (Alder Hey). Saliva samples will be
sent to University Department Laboratory located in the
Liverpool Women's Hospital for processing (Figure 1).
Informed Consent
The parent(s)/guardian(s) of each potentially eligible
patient will be informed of the study's objectives and
overall requirements after birth when the baby has
achieved respiratory and haemodynamic stability. The
Investigator will explain the study fully using the Patient
Information Leaflet. The parent/guardian will then be
given at least 12 hours to consider the study. If a parent/
guardian is willing for the patient to participate in the
study, he/she will be requested to give written consent.
The Informed Consent Form will be signed and person-
ally dated by both a parent/guardian and the investigator.
A copy of the signed form will be provided to the par-
ent(s)/guardian(s), another copy will be placed in they
patient record, and the original retained with the research
record. Nursing staff may be involved in describing the
trial to the patient and his/her parent(s)/guardian(s).
A similar procedure will be followed for the elements of
the study relating to MRI scans and population pharma-
cokinetics. An investigator will introduce the MRI scan/
population pharmacokinetic study, leave the specific
information leaflet and return after at least 12 hours.
Data Management
Data will be collected on a case report form (CRF) starting
at the time of recruitment. Data will be entered anony-
mously on to a password-protected database which will
be stored in a secure office. All CRF hard copies will be
duplicated and will be stored in a locked filing cabinet
within the same office. Access to the database will be
restricted to the investigators.
In accordance with R&D policy at LWH, the notes of all
participants will be marked with a sticker to indicate study
participation. A tag will be used to identify electronic
records of study participants. All clinical records of study
participants will be retained for 20 years. All paper and
electronic records relating to the study will be retained for
20 years.
Subject Withdrawal
Patients may be withdrawn from treatment for any of the
following reasons:
a) Parent/legal representative withdraws consent.
b) Unacceptable toxicity (a potential unacceptable toxic-
ity is defined as sustained tachycardia i.e. heart rate greater
than 220 beats per minute for more than 30 minutes in a
60 minute period, in the presence of a high thyroid hor-
mone blood concentration)
c) Intercurrent illness preventing further treatment.
d) Development of serious disease.
e) Any change in the patient's condition that justifies the
discontinuation of treatment in the clinician's opinion.
If a parent/legal representative wishes to withdraw an
infant from trial treatment, centres will document the rea-
son and explain the importance of remaining on trial fol-
low-up and, if willing, to continue to have data collected
as per trial schedule, or, failing this, to attend clinic and
allow routine follow-up data to be used for trial purposes.
Generally, follow-up will continue unless the patient
explicitly withdraws consent for follow-up. Following
withdrawal from trial treatment, patients will be treated
according to usual local clinical practice.
The parents/legal guardians of patients who voluntarily
withdraw from the trial have previously consented to fol-
low-up in the trial. Data up to the time of withdrawal will
be included in the trial if anonymised. If the parents/legal
guardians explicitly state their wish not to contribute fur-Trials 2008, 9:17 http://www.trialsjournal.com/content/9/1/17
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ther data to the study, the investigators will be informed
and a withdrawal CRF will be completed.
Statistical Consideration
Sample Size Calculation
A sample size of 64 in each group will have 80% power to
detect a difference between the means of the thyroxine
and placebo groups of 0.67 mm (0.5*SD) for the out-
come subarachnoid space at 36 weeks' CGA. This assumes
that the common standard deviation is 1.3 mm and anal-
ysis is based on using a two group t-test with a 0.05 two-
sided significance level. The value for the SD is taken from
Armstrong et al[54] who report subarachnoid space as an
indirect method of brain growth in preterm infants.
To ensure the appropriateness of the SD used in our calcu-
lations we will run an internal pilot after the first 30
infants have been randomised. We will compare the SD of
Patient Flow During Trial Figure 1
Patient Flow During Trial.
 
Baby born under 28 weeks' gestation admitted to the Neonatal Unit  
p 
Check eligibility 
p 
Discuss study with parents, using the patient information sheet 
p 
Obtain written consent and study randomisation number   
p 
Take blood from mother for TT4, FT4, TT3, FT3, TSH, TPO, TRAB, cortisol 
p 
Prescribe thyroxine/ placebo from Pharmacy at 8mcg/kg birth weight/day until 32 weeks CGA. 
p 
Obtain bloods for TT4, FT4, TT3, FT3, TSH, early morning cortisol and ACTH level to coincide with routine bloods before commencing treatment 
p 
Obtain salivary cortisol (100microlitres) at 0:900, 15:00, 21:00 before commencing treatment 
p 
Measure infants head circumference, lower leg length (knemometry), weight before commencing treatment 
p 
Obtain bloods for TT4, FT4, TT3, FT3, TSH, early morning cortisol and ACTH level to coincide with routine bloods on Day 14 
p 
Obtain salivary cortisol (100microlitres) at 0:900, 15:00, 21:00 on Day 14 
p 
Measure infants head circumference, lower leg length (knemometry), weight on Day 14 
p 
Discuss brain MRI scanning with parents at a time when the infant is clinically stable 
p 
Obtain written consent for MRI scanning  
p 
Obtain bloods for TT4, FT4, TT3, FT3, TSH to coincide with routine bloods on Day 21 
p 
Measure infants head circumference, lower leg length (knemometry), weight on Day 21 
 
Obtain bloods for TT4, FT4, TT3, FT3, TSH, early morning cortisol and ACTH level to coincide with routine bloods on Day 28 
p 
Obtain salivary cortisol (100microlitres) 0:900, 15:00, 21:00 on Day 28 
p 
Measure infant’s head circumference, lower leg length (knemometry), weight on Day 28 
p 
Obtain bloods for TT4, FT4, TT3, FT3, TSH, early morning cortisol and ACTH level to coincide with routine bloods at 36 Weeks CGA 
p 
Obtain salivary cortisol (100microlitres) at 0:900, 15:00, 21:00 at 36 Weeks CGA 
p 
Measure infant’s head circumference, lower leg length (knemometry), weight at 36 Weeks CGA 
p 
Measure width of subarachnoid space using cranial ultrasound at 36 Weeks CGA 
p 
Measure thyroid gland size at 36 Weeks CGA 
p 
Brain MRI scan at if consent obtained at term equivalent Trials 2008, 9:17 http://www.trialsjournal.com/content/9/1/17
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these 30 infants with the standard deviation of Armstrong
et al[54]. An internal pilot[49] can be used to increase but
not decrease the size of the study. Assuming the 20% loss
to follow up that we have experienced in an ongoing trial
on the unit, we aim to recruit and randomise 150 infants
with gestation below 28 weeks'.
Analysis
Final analysis of the primary and secondary outcome
measures will be carried out at study closure defined as the
date of database lock. The principle of intention to treat
analysis will be performed blind to treatment allocation.
Longitudinal data will be analysed using mixed models
with survival outcomes analysed using Kaplan-Meier
curves with log-rank tests and Cox Proportional Hazard
models. The potential for jointly modelling longitudinal
data with survival outcomes will be explored[50]. The use
of these regression models will allow us to consider the
relationships between thyroid status and factors that
could modulate the effect of thyroid supplementation. A
separate statistical analysis plan will be developed prior to
the internal pilot.
A secondary per protocol analysis will also be considered.
Adverse Event Reporting and Safety Evaluations
Definitions
Adverse event (AE)
Any untoward medical occurrence in a subject recruited to
a clinical trial, including occurrences which are not neces-
sarily caused by or related with the treatment. An adverse
event can be any unfavourable and unintended sign or
symptom associated with the use of a medicinal product
whether or not related to that product.
Adverse reaction (AR)
Any untoward and unintended response in a subject to an
investigational medicinal product which is related to any
dose administered to that subject.
Serious adverse event (SAE), serious adverse reaction (SAR) or 
unexpected serious adverse reaction
Any adverse event, adverse reaction or unexpected adverse
reaction, respectively, that
a) results in death,
b) is life-threatening,
c) requires hospitalisation or prolongation of existing
hospitalisation,
d) results in persistent or significant disability or incapac-
ity, or
e) consists of a congenital anomaly or birth defect.
Expected Serious Adverse Events
Extremely premature babies below 28 weeks' gestation
constitute a high risk population: the following are seri-
ous adverse events and incidence rates which could be rea-
sonably expected for this group of babies during the
course of the study (Table 1).
Reporting Serious Adverse Events
All expected Serious Adverse Events (SAE) (Table 1) will
be recorded in the case report forms (CRF). All deaths or
suspected overdoses will be reported using the SAE report
forms (See Appendix) to the Chief Investigator (CI)
within 24 hours and will be reviewed by the DMEC at reg-
ular intervals throughout the trial. The trial sponsor will
collate and submit annual safety reports to MHRA and
ethics committee. However, the MHRA, the trial sponsor
and the chair of the MREC may also be informed about
severe adverse events by the DMEC chair if considered
appropriate.
A standard reporting procedure will be provided on the
reverse side of all SAE forms. A Trial Standard Operating
Procedure with detailed information on reporting proce-
Table 1: List of Expected Serious Adverse events
Adverse event Estimated incidence
a) death 20%*
b) necrotising enterocolitis or focal intestinal perforation diagnosed on clinical grounds, or at surgery 15%*
c) intracranial abnormality (parenchymal haemorrhage or focal white matter damage) on cranial ultrasound 15%*
d) requirement for supplementary oxygen 28 days after birth 55%*
e) patent ductus arteriosus requiring medical or surgical management 25%*
f) retinal surgery for retinopathy of prematurity 5%*
g) sustained tachycardia (greater than 220 beats per minute for more than 30 minutes in a 60 minute period) 20%**
h) pulmonary haemorrhage 5%**
i) persistent weight loss after 14 days after birth in the absence of infection. 10%**
* based on incidence of these complications at Liverpool Women's Hospital
** based on incidences estimated by the investigatorsTrials 2008, 9:17 http://www.trialsjournal.com/content/9/1/17
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dures will also be kept in site files at each 'trial station' in
each centre. Copies of all correspondence relating to
reporting will be maintained in the Investigator's files.
All adverse events whether or not they are attributable to
the study intervention will be reported on case report
forms. These will be reviewed by the investigators
monthly to determine if there is reasonable suspected
causal relationship to the intervention. If there is evidence
that there may be a novel causal relationship with the
intervention, then the procedure for expedited reporting
of suspected unexpected serious adverse reactions will be
followed (section 5.4 below). All adverse events will be
followed until satisfactory resolution or until the investi-
gator responsible for the care of the participant deems the
event to be chronic or the patient to be stable.
Suspected Unexpected Serious Adverse Reactions
Given the vulnerability of these infants, the Chief Investi-
gator and the Principal Investigators will review all serious
adverse events in order to detect Suspected Unexpected
Serious Reactions (SUSARs), involving other members of
the Trial Management Group as appropriate. The proce-
dure for identifying and reporting Suspected Unexpected
Serious Adverse Reactions will be as follows.
All deaths or overdoses will be reviewed by the Chief
Investigator (CI) or in his absence another member of the
Trial Management Group. For each death the CI, or his
deputy, will make a judgement about whether the nature
or severity of the circumstances surrounding the death is
consistent with adverse drug reactions associated with lev-
othyroxine. Other members of the Trial Management
Group who are available at the time may contribute to a
discussion prior to the judgement. The judgement will
take place within 24 hours of the notification of a death.
If the nature or severity of the events leading up to the
death are considered to be related to the study medication
but inconsistent with what is known about levothyroxine,
the allocation concealment for the affected infant will be
broken by the sponsor. In the event of a death occurring
in association with events that are not consistent with the
information contained in this protocol and the infant was
allocated to levothyroxine, the event will be labelled as a
Suspected Unexpected Serious Adverse Reaction (SUSAR).
If an overdose is thought to have led to a serious adverse
event not listed in section 5.2 then the event will be
labelled as a SUSAR. All events labelled as SUSARs will be
reported to the sponsor within 24 hours of the decision
being made. All SUSARs will be reported to the competent
regulatory authority (MHRA) with a copy to the Sponsor
as soon as possible but not later than 7 working days.
The Trial Management Group will meet monthly in order
to review all other Serious Adverse Events. The Group will
consider whether each SAE is consistent with the informa-
tion contained in this protocol about the nature and
severity of adverse drug reactions associated with levothy-
roxine (including literature cited in the protocol). The CI
or his deputy will make a judgement about whether the
nature or severity of the circumstances surrounding the
death is consistent with the information contained in this
protocol about the nature and severity of adverse drug
reactions associated with levothyroxine. If the nature or
severity of the SAE is judged to be inconsistent with the
information contained in this protocol the allocation con-
cealment for the affected infant will be broken. In the
event that a SAE occurs in association with events that are
not consistent with the information contained in this pro-
tocol and the infant was allocated to levothyroxine, the
event will be labelled as a Suspected Unexpected Serious
Adverse Reaction (SUSAR) and reported as above.
Trial Oversight
Data Monitoring and Ethics Committee (DMEC)
An independent Data Monitoring and Ethics Committee
(DMEC) has been formed. During the period of recruit-
ment, interim summaries of results will be supplied, in
strictest confidence, to the DMEC by the trial statistician.
At its first meeting the DMEC will determine the fre-
quency of its meetings and the data to be supplied for the
meetings. Meetings of the full committee will be arranged
periodically as agreed by the full DMEC at the first meet-
ing. In the light of interim data and emerging evidence
from other studies, the DMEC will inform the Trial Steer-
ing Committee if, in their view, there is proof beyond rea-
sonable doubt that the data indicate that any part of the
protocol is indicated or contra-indicated either for all
infants or for a particular subgroup of trial participants.
The decision to inform the steering committee will be, in
part, based on statistical considerations. Appropriate crite-
ria for the 'proof beyond reasonable doubt' cannot be
specified precisely, but a difference of at least 3 standard
deviations of a major endpoint may be needed to justify
halting or modifying the study prematurely. If a 2–5 fold
increase, depending on the event, is seen in any of the
expected serious adverse events across both groups, then
an emergency DMEC meeting will be called. However,
discretion will used around the cut-off points based on
discussion with the Trial Management Group members.
Trial Steering Committee (TSC)
A trial steering committee will be set up which will have
overall supervision of the trial. It will meet (generally by
telephone conference) prior to commencement of the
trial and then at least 6 monthly until completion. A meet-
ing of the TSC will be held within a month of every DMEC
meeting to consider their recommendations.Trials 2008, 9:17 http://www.trialsjournal.com/content/9/1/17
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Significance of the Trial
The optimal way to manage transient hypothyroidism in
preterm infants under 28 weeks' gestation is unclear. In
part, this is because infants born at extreme prematurity
have different physiology from older children, preterm
delivery leads to some unique complications and infants
undergo striking maturational changes during their stay
on the intensive care unit. Thus, studies that test whether
manipulation of the thyroid system alters outcome need
to be based on a refined understanding of how thyroid
supplementation relates to premature birth, its complica-
tions and subsequent development. Recent guidelines
from the National Institute for Clinical Excellence (NICE)
emphasise this need for including such children in rigor-
ous studies of interventions rather than treating them on
an ad hoc basis. To date, other studies have not reported
serious harm as a consequence of T4 therapy in preterm
infants. The role of thyroid hormone therapy in preterm
infants under 28 weeks gestation will be established or
refuted as a consequence of this trial. The information
acquired will be of interest to neonatologists, obstetri-
cians, paediatric endocrinologists and a wide circle of gen-
eral paediatricians in their management of preterm
infants. This will help to ensure those who need treatment
receive it, and those who do not need treatment will not
receive inappropriate therapy.
This study will yield novel data about how supplementa-
tion with thyroid hormone of an extreme preterm infant
modulates the hypothalamic-pituitary-adrenal axis,
somatic growth and brain size at term. It is an explanatory
trial designed to provide data that will provide essential
underpinning to pragmatic trials of treatment efficacy by
clarifying the factors that need to be accounted for in
large-scale studies and providing estimates of variability
in key confounders.
Ethical issues
There is no evidence that T4 supplementation causes
harm in our target population. The most likely negative
effect of T4 supplementation (persistent tachycardia) is
relatively trivial. The more serious adverse effect of
impaired neurodevelopment was shown in a post hoc anal-
ysis and only applied to more mature babies. That same
analysis showed that there was a possible advantage for
the very immature babies, who are the subjects of this
study. The neonatal community and clinicians in our unit
are at equipoise concerning the value of T4 supplementa-
tion in this patient group. We will ensure that our results
are suitable for meta-analysis with the work of other
groups. Thus we believe that it is ethical to ask parents to
allow their child to be randomised to T4 or placebo, given
the monitoring that will be included in the study design.
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